[1]Wang L M, Zhou B, Zhao Z P, et al. Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18[J]. Lancet, 2021, 398(10294): 53-63.
[2]Mu L, Liu J M, Zhou G H, et al. Obesity prevalence and risks among Chinese adults: findings from the China PEACE million persons project, 2014-2018[J]. Circ Cardiovasc Qual Outcomes, 2021, 14(6): e007292.
[3]Wang L M, Peng W, Zhao Z P, et al. Prevalence and treatment of diabetes in China, 2013-2018[J]. JAMA, 2021, 326(24): 2498-2506.
[4]Chen K, Shen Z W, Gu W J, et al. Prevalence of obesity and associated complications in China: a cross-sectional, real-world study in 15.8 million adults[J]. Diabetes Obes Metab, 2023, 25(11): 3390-3399.
[5]Wang Y F, Zhao L, Gao L W, et al. Health policy and public health implications of obesity in China[J]. Lancet Diabetes Endocrinol, 2021, 9(7): 446-461.
[6]孙晓冰,庄向慧, 吴炯, 等. 体重调整腰围指数与城市老年人糖尿病和高血压的相关性研究[J]. 兰州大学学报(医学版), 2026, 52(6): 72-80.
[7]陈俊,项永兵. 早发性结直肠癌危险因素的流行病学前瞻性研究进展[J]. 中华肿瘤防治杂志, 2025, 32(6): 376-381.
[8]赖敏,袁文臻. 肥胖导致慢病机制假说[J]. 空军军医大学学报, 2023, 44(3): 284-288.
[9]Rohm T V, Meier D T, Olefsky J M, et al. Inflammation in obesity, diabetes, and related disorders[J]. Immunity, 2022, 55(1): 31-55.
[10]黄婧荷, 郭立新. 内脏脂肪与2型糖尿病相关性的研究进展[J]. 中华糖尿病杂志, 2024, 16(10): 1147-1151.
[11]Luo J Q, Wang Y, Mao J X, et al. Features, functions, and associated diseases of visceral and ectopic fat: a comprehensive review[J]. Obesity, 2025, 33(5): 825-838.
[12]Gao J, Dong X W, Shi X L, et al. The association between pancreatic diseases and pancreatic fat content: a cross-sectional study from the UK Biobank[J]. Front Endocrinol, 2025, 16: 1591652.
[13]Tushuizen M E, Bunck M C, Pouwels P J, et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes[J]. Diabetes Care, 2007, 30(11): 2916-2921.
[14]中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021,13(4):95.
[15]柳勇. 基于磁共振Dixon技术的肝脏及胰腺脂肪半定量分析及其临床意义[D]. 苏州大学, 2018.
[16]Potter A W, Friedl K E. Cross-sectional analysis of visceral adipose tissue associations with obesity-related disease[J]. Am J Clin Nutr, 2025, 122(5): 1489-1497.
[17]Mittelman S D, Van Citters G W, Kirkman E L, et al. Extreme insulin resistance of the central adipose depot in vivo[J]. Diabetes, 2002, 51(3): 755-761.
[18]Arner P. Insulin resistance in type 2 diabetes: role of fatty acids[J]. Diabetes Metab Res Rev, 2002, 18(S2): S5-S9.
[19]Hotamisligil G S. Inflammation and metabolic disorders[J]. Nature, 2006, 444(7121): 860-867.
[20]Badmus O O, Hillhouse S A, Anderson C D, et al. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways[J]. Clin Sci, 2022, 136(18): 1347-1366.
[21]Kakazu E, Mino M, Kanto T. Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease[J]. Clin Mol Hepatol, 2025, 31(3): 771-795.
[22]Le M D, Wu Y L, Berry J D, et al. Associations of liver fat content with cardiometabolic phenotypes and outcomes in a multi-ethnic population: results from the Dallas Heart Study[J]. Diabetes Obes Metab, 2023, 25(2): 586-595.
[23]Lee W H, Kipp Z A, Bates E A, et al. The physiology of MASLD: molecular pathways between liver and adipose tissues[J]. Clin Sci, 2025, 139(18): 1015-1046.[24]Vujasinovic M, Demir I E, Marchegiani G, et al. International multidisciplinary consensus report on definitions, diagnostic criteria, and management of fatty pancreas: a joint statement endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG[J]. United European Gastroenterol J, 2026, 14(1): e70185.
[25]Dong X W, Zhu Q T, Yuan C C, et al. Associations of intrapancreatic fat deposition with incident diseases of the exocrine and endocrine pancreas: a UK biobank prospective cohort study[J]. Am J Gastroenterol, 2024, 119(6): 1158-1166.
[26]Van Der Zijl N J, Goossens G H, Moors C C, et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on beta-cell function in individuals with impaired glucose metabolism[J]. J Clin Endocrinol Metab, 2011, 96(2): 459-467.
[27]Heni M, Machann J, Staiger H, et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study[J]. Diabetes Metab Res Rev, 2010, 26(3): 200-205.
[28]Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause[J]. Diabetologia, 2008, 51(10): 1781-1789.
[29]Dobre M Z, Virgolici B, Timnea O. Key roles of brown, subcutaneous, and visceral adipose tissues in obesity and insulin resistance[J]. Curr Issues Mol Biol, 2025, 47(5): 343.
[30]Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome[J]. J Clin Invest, 2006, 116(7): 1784-1792.
[31]Newsome P N, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12): 1113-1124.
|